Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | HTR1B | P28222 | 3/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 3/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241416 | 0.84 | TAAR1 (0.57) | TAAR1PARP1RAD52KMT2ANISCH | |
| SCHEMBL2244435 | 0.79 | TAAR1 (0.61) | TAAR1PARP1RAD52KMT2ANISCH | |
| SCHEMBL14563132 | 0.79 | TAAR1 (0.51) | TAAR1PARP1RAD52KMT2ANISCH | |
| SCHEMBL2243420 | 0.78 | HRH3 (0.57) | TAAR1PARP1HTR7HRH3 | |
| SCHEMBL8110408 | 0.78 | TAAR1 (0.53) | TAAR1PARP1RAD52KMT2ANISCH | |
| Hydrochloric Acid SCHEMBL2243649 | 0.77 | TAAR1 (0.55) | TAAR1PARP1RAD52KMT2ANISCH | |
| SCHEMBL2244595 | 0.76 | LMNA (0.43) | TAAR1HTR1BKMT2AALDH1A1 | |
| SCHEMBL14563133 | 0.75 | TAAR1 (0.52) | TAAR1PARP1RAD52KMT2ANISCH | |
| SCHEMBL2244011 | 0.75 | TAAR1 (0.58) | TAAR1PARP1RAD52KMT2ANISCH | |
| SCHEMBL2243043 | 0.72 | HDAC1 (0.40) | TAAR1HTR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170879-B1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2170879-B1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2013-01-16 | — | — | EP | disclosed |
| US-8008279-B2 | Compound—827 | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-8008279-B2 | Compound—827 | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-8008279-B2 | Compound—827 | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| EP-2170879-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009001129-A9 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009001129-A9 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | WO | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| WO-2009001129-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009001129-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012077-A1 | Novel Compound - 827 | CTSS, CTSF, CTSB | TAAR1 4785/4885HTR1B 3843/4885PARP1 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.